TMS

Quick links to important sections

TMS

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of TMS

Quick Facts

Property Description
Active Ingredient Tiemonium methylsulfate
Forms Tablets, Injectable Solution
Pharmacological Class Antispasmodic
Common Use Relief of smooth muscle spasms
Origin Synthetic (Quaternary Ammonium)

What Type of Medicine is Tiemonium Methylsulfate (TMS)?

Tiemonium methylsulfate (TMS) is a synthetic pharmaceutical compound that functions as an antispasmodic agent, primarily used to relieve involuntary muscle contractions. Chemically, it is classified as a quaternary ammonium antimuscarinic, a type of compound that specifically affects the signaling pathways of the involuntary nervous system, an action which pharmacological studies have extensively documented. This classification confirms the drug's specialized role in targeting neurochemical pathways responsible for contraction. The medication is prepared as a single-ingredient drug available in two main dosage forms: tablets for easy oral administration and a sterile injectable solution for parenteral delivery, a dual format often relied upon for managing varying degrees of spasmodic pain intensity.


Composition and General Purpose of TMS

The activity of the medication is entirely attributed to the active ingredient, Tiemonium methylsulfate, which is formulated with pharmaceutical excipients for solid forms or a sterile aqueous solution for the injectable form. The primary function of TMS is to induce spasmolysis, the targeted relaxation of the excessive, involuntary contraction of smooth muscles found in the walls of organs such as the intestines, bile ducts, and urinary tract. Clinical experience confirms that this mechanism is highly effective in reducing the pain associated with spasms in these internal organ systems. This action provides relief by resolving the painful cramping that is characteristic of disorders in the gastrointestinal, biliary, and urinogenital tracts, making it a clinically recognized choice for managing the pain component of conditions like intestinal colic.

What side effects are possible with TMS?

Possible Side Effects and Safety Information for Tiemonium Methylsulfate

Regulatory documentation for Tiemonium methylsulfate, an antimuscarinic antispasmodic, structures its safety profile around the drug's intended action on smooth muscles. Side effects are often classified as very rare in some official prescribing information, though common anticholinergic effects are frequently noted.


Official Adverse Reaction Scope

Adverse reactions documented in international regulatory sources primarily involve the autonomic nervous system. The most common or expected effects include dry mouth (thirst), constipation, dizziness, and blurred vision. These effects are generally reflective of the drug's antimuscarinic action.

System-Organ Class Noted Adverse Reactions (Regulatory-Aligned)
Gastrointestinal Constipation
Ocular (Eye) Blurred vision
Nervous System Dizziness, Headache
Cardiac Palpitations, Tachycardia

Serious Adverse Reactions and Safety Restrictions

Specific serious adverse reactions highlighted in official labeling include urinary retention and, particularly with parenteral administration, a risk of hypotension and pronounced tachycardia. The risk of these cardiovascular events is noted to be linked to the speed of injection.

Use of the medicine is contraindicated in patients with certain pre-existing conditions, including Glaucoma, disorders of the prostate or urinary bladder (due to the risk of retention), and certain obstructive gastrointestinal conditions like paralytic ileus. Additionally, specific cautions are required for patients with coronary insufficiency, renal insufficiency, and hepatic insufficiency, as defined by regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section outlines the officially documented overdose profile for Tiemonium methylsulfate (TMS), based strictly on government-approved prescribing information and regulatory-mandated sources.

Documented Overdose Manifestations

Official regulatory labeling lists specific clinical signs that may occur in cases of Tiemonium methylsulfate overdosage:

  • Retention of Urine: The occurrence of occasional urine retention.
  • Tachycardia: A documented potential for rapid heart rate.
  • Agitation: Explicitly listed as a possible central nervous system manifestation.
  • Respiratory Disorders: Noted as a possible outcome of overdosage.
  • Peripheral Effects: Cited as a general consequence of excessive exposure.

Official Emergency Actions

Regulatory documents consistently emphasize the need for immediate professional guidance in overdose situations:

  • Required Action: Individuals must consult immediately with the attending practitioners or seek medical advice in all cases of suspected or confirmed overdose.
  • Antidote: Official labeling does not specify a pharmacological antidote for Tiemonium methylsulfate overdosage.

The regulatory profile mandates prompt recognition of the documented symptoms and immediate consultation with a healthcare professional for symptomatic management, as required procedural steps are not universally mandated for home use.

Therapeutic Uses of TMS

Quick Facts

  • Offers management for symptoms of major depressive disorder (MDD).
  • Used as a treatment option for obsessive-compulsive disorder (OCD).
  • Provides assistance with reducing the frequency of migraine headaches.
  • May support short-term cessation of smoking in adults.

What TMS Treats: Main Uses and Benefits

Transcranial Magnetic Stimulation (TMS) is a treatment modality for certain neurological and psychiatric conditions. It is used to address the manifestations of major depressive disorder (MDD), particularly in individuals who have not achieved adequate symptom reduction from prior antidepressant medication. For this population, TMS serves as an option to support their treatment plan.

Additionally, TMS is indicated for obsessive-compulsive disorder (OCD) as an adjunct treatment for adults when conventional treatments have not provided sufficient improvement. The procedure also provides management for reducing the frequency of pain associated with certain types of migraine headaches.

TMS is further utilized to support short-term smoking cessation in adults. Clinical data supports the use of this modality to assist in managing symptoms across these specified therapeutic domains.

Eligibility and Restrictions for Use

Who Can and Cannot Use Transcranial Magnetic Stimulation (TMS)?

Transcranial Magnetic Stimulation (TMS) is typically indicated for adults with Major Depressive Disorder (MDD) who have not achieved satisfactory improvement from prior antidepressant medication. It is also approved for certain other conditions, such as Obsessive-Compulsive Disorder (OCD) and smoking cessation, depending on the specific device and regulatory approvals.


Contraindications and Exclusion Criteria

TMS is not a suitable treatment for everyone. The most significant absolute contraindication involves the presence of ferromagnetic or electronically activated implants in or near the head, as the strong magnetic fields can heat up, move, or otherwise damage these devices.

Contraindication Category Examples of Excluded Patients
Metallic Implants Cochlear implants, aneurysm clips or coils, metallic shrapnel in or near the head, and some facial tattoos with metallic ink.
Electronic Devices Implanted neurostimulators, vagus nerve stimulators (VNS), and cardiac pacemakers or defibrillators.
Medical History History of seizures or conditions that lower the seizure threshold, although this is a relative contraindication often assessed on a case-by-case basis.

A thorough screening process is essential to determine patient eligibility and safety before initiating TMS therapy.

What should I know about interactions with other medicines?

The official interaction profile for Tiemonium methylsulfate (TMS) is primarily defined by pharmacodynamic effects resulting from its classification as an antimuscarinic agent. Regulatory documents do not specify pharmacokinetic interactions related to CYP enzyme metabolism, drug transport proteins, or mandatory timing separation rules for administration.

Documented Interaction Categories

Interaction Mechanism Interacting Substances
Pharmacodynamic Reinforcement Anticholinergic Agents, Tricyclic Antidepressants, Phenothiazine Antipsychotics, First-generation Antihistamines, and Monoamine Oxidase Inhibitors (MAOIs).
Pharmacodynamic Interference Gastrointestinal Motility Agents (Prokinetics).

Regulatory Profile Summary

The official regulatory structure classifies interactions based on additive anticholinergic burden, noting that co-administration with other agents possessing similar properties may enhance the resulting effects. This reinforcement carries a risk of potentiation. Conversely, the official profile notes that the efficacy of prokinetic agents may be reduced due to the opposing actions of the antispasmodic. There are no specific drug-drug combinations formally labeled as contraindicated in the available regulatory documentation, and no documented interactions are specified for food, alcohol, or herbal products.

Mechanism of Action

Competitive Blockade of Visceral Signaling

This domain addresses the drug's primary interaction: acting as a competitive antagonist at the peripheral Muscarinic Acetylcholine Receptors ( mAChRs) on smooth muscle. By binding to these receptors, Tiemonium methylsulfate (TMS) interrupts the signal from the parasympathetic nervous system that commands muscle contraction. This action modifies the signal cascade, resulting in a decrease in parasympathetic cholinergic efferent signaling.


Dual Action on Cellular Contraction Dynamics

Beyond receptor blockade, TMS engages a secondary direct action on the smooth muscle cell membrane by binding to phospholipids. This convergence of antagonism and membrane stabilization modulates the intracellular availability of calcium ions ( Ca^2+), the essential molecular trigger for muscle contraction. This dual mechanism impairs the ability of muscle fibers to sustain excessive, involuntary contractile force, leading to spasmolysis, defined as the pharmacological reversal of excessive smooth muscle contraction.


Structurally Enforced Peripheral Selectivity

The chemical structure of TMS, a quaternary ammonium compound, is fundamental to its mechanistic scope. This structure limits the drug's ability to cross the blood-brain barrier, concentrating its action almost exclusively on muscarinic targets located on the peripheral visceral smooth muscle. This inherent peripheral selectivity focuses the mechanism on modulating smooth muscle contractility.

Dosage and Administration Information

How Tiemonium Methylsulfate (TMS) is Used

The usage protocol for Tiemonium methylsulfate is defined to manage smooth muscle spasms, with the administration strategy dictated by the severity and duration of the condition. Tiemonium methylsulfate is a quaternary ammonium antimuscarinic agent. The medicine is available in two distinct dosage forms: oral tablets (50 mg strength) and a sterile injectable solution (5 mg per 2 mL ampoule).


Official Administration Guidelines

Acute vs. Maintenance Use

For acute, severe spasms, the injectable solution is administered via the Intramuscular (IM) or slow Intravenous (IV) route under professional supervision. The typical parenteral dose is 5 mg to 10 mg, which may be repeated up to three to four times daily. The injectable form is designated for short-term use.

For maintenance therapy or less severe conditions, the treatment is delivered via the oral route using the 50 mg tablets. The standard regimen for oral use is two to three times per day, with the total daily dose not exceeding 300 mg.


Procedural and Population Constraints

All parenteral administration must be slow and controlled, and the injectable solution should not be mixed with other substances in the same line without confirmation of compatibility. The protocol generally advises caution and requires potential dose adjustment for older adults due to increased sensitivity, and specific modifications are also necessary for patients with known renal or hepatic impairment.

Recent Clinical Evidence

TMS: Recent Clinical Evidence

Recent clinical research on Transcranial Magnetic Stimulation (TMS), particularly repetitive TMS (rTMS) and Theta Burst Stimulation (TBS), has focused on expanding its use beyond major depressive disorder (MDD) and optimizing treatment protocols. This research consistently highlights the non-invasive nature and favorable safety profile of TMS.


Core Findings in Treatment Efficacy

Clinical trials, including sham-controlled studies and large systematic reviews, generally support the beneficial effect of TMS in patients with treatment-resistant depression (TRD) who have not responded to adequate courses of antidepressant medication. Response rates for rTMS in real-world settings are often reported to be in the range of 30% to 40% for remission, with the effects sometimes lasting for several months.

  • Quality of Life: Studies suggest TMS may be associated with clinically meaningful improvements in overall quality of life (QoL) for adults with MDD, often showing sustained QoL improvements beyond the acute treatment phase.
  • Protocols: Research continues to explore optimized stimulation protocols, including high-frequency (HF-rTMS), intermittent Theta Burst Stimulation (iTBS), and deep TMS (dTMS), with iTBS protocols demonstrating the potential for comparable results in significantly shorter treatment times.

Expanding Indications

The research base is broadening for other neurological and psychiatric conditions. Recent findings have contributed to regulatory clearances for new indications.

Condition Research Summary
Obsessive-Compulsive Disorder (OCD) Studies support the use of specific dTMS protocols for reducing core OCD symptoms, particularly in patients who have not responded to standard treatments.
Migraine Specific single-pulse TMS (sTMS) devices have been investigated for the acute treatment of migraine with aura, providing a non-pharmacological option.
Chronic Pain Investigations into rTMS targeting the motor cortex suggest a potential role in managing certain chronic neuropathic pain syndromes, though evidence remains less definitive compared to mood disorders.

Safety and Tolerability

TMS is generally considered safe and well-tolerated. Common side effects are mild and temporary, such as scalp discomfort, pain, or headache. The risk of serious adverse events, such as seizure induction, is low when established safety guidelines are followed.

Frequently Asked Questions (FAQ)

Common questions about TMS (FAQ)


Q: Is TMS considered a common treatment for depression?

Official medical necessity criteria and regulatory guidelines indicate that TMS is an FDA-cleared treatment for Major Depressive Disorder in adult patients. It is considered medically necessary for individuals who have not achieved a satisfactory improvement from prior standard antidepressant treatments.


Q: What is the total duration of a standard TMS treatment course?

According to the official treatment protocols, a standard course of TMS is typically delivered daily, five times per week. The total duration of the acute treatment phase generally lasts between 4 to 6 weeks, which involves up to 30 to 36 total sessions.


Q: Can TMS treatment be used alongside medication?

Official clinical guidelines note that concurrent psychotherapy and/or antidepressant medication treatment is allowable and often practiced. Official guidelines permit TMS to be used in conjunction with other standard therapeutic approaches.


Q: Why is TMS sometimes called 'non-invasive'?

TMS is described as non-invasive because the procedure does not require surgery, cutting of the skin, or penetration into the body. The treatment is delivered using a magnetic coil placed on the scalp and is performed without the need for general anesthesia or sedation.


Q: Is there scientific research available to back up the claims about TMS?

Yes, regulatory decisions, including FDA clearance, are supported by clinical trials, systematic reviews, and large real-world data studies. This evidence base supports the defined role of TMS in treating certain neurological and psychiatric conditions.


Q: How do doctors decide on the stimulation intensity for TMS?

The treatment intensity is customized for each individual through a process called 'mapping' that is performed before the first session. During mapping, the doctor identifies the patient's motor threshold (MT)—the minimum magnetic energy needed to cause a slight movement—which is then used to set the prescribed stimulation level.


Q: Why is TMS sometimes used when psychotherapy hasn't helped?

TMS is indicated for patients with Major Depressive Disorder who have not achieved satisfactory improvement from prior standard treatments. This includes antidepressant medication and/or talk therapy (psychotherapy).


Q: Is TMS approved for use in teenagers or children?

FDA clearance for certain TMS devices indicates their availability for adults. Currently, official evidence supports the use of certain TMS devices as an adjunct therapy for adolescents aged 15 to 21 years.


Q: What's the difference between TMS and ECT (Electroconvulsive Therapy)?

Official medical information states that TMS is a non-invasive procedure performed without the need for anesthesia or sedation. The procedure is performed while the patient is awake and alert.


Q: Does TMS feel painful?

While the sensation is generally described as not painful, patients may experience mild scalp discomfort, pain, or a tapping sensation at the site of the coil. This discomfort is usually mild and often decreases over the course of the treatment.


Q: Is it common to feel tired after a TMS session?

Clinical guidance documents list sleep disruption, which can lead to fatigue or tiredness, as one of the common, mild side effects that patients may experience following a TMS session.


Q: Can I drive immediately after getting TMS treatment?

Since the procedure is non-invasive and does not involve the use of sedation, patients are often able to resume daily activities, including driving and working, immediately following a treatment session.


Q: How does TMS affect my ability to work or study?

Since the procedure is non-invasive and does not involve the use of sedation, patients are typically able to resume normal activities, including working and studying, immediately following the treatment session.


Q: Are there different types of TMS technology?

Yes, there are different FDA-cleared approaches and protocols for TMS treatment. These include repetitive TMS (rTMS), Deep TMS (dTMS), and intermittent Theta Burst Stimulation (iTBS), which vary in stimulation pattern, coil type, and overall treatment duration.


Q: What's the mechanism that causes the clicking or tapping sensation during TMS?

The sound and physical sensation are produced by the rapid delivery of the magnetic pulses from the coil against the patient's head. Due to the loud clicking noise produced, official protocols include the use of earplugs for patient safety.


Q: Are there specific parts of the brain that TMS targets?

Yes, the protocols for Major Depressive Disorder typically involve positioning the magnetic coil over a specific area known as the left dorsolateral prefrontal cortex (DLPFC). This target is chosen based on its established role in mood regulation.


Q: How long do the positive effects of TMS typically last?

Research and medical criteria indicate that the response experienced by patients may be sustained for several months following the conclusion of the treatment course.


Q: How does the magnetic field in TMS compare to an MRI?

The magnetic field generated by most TMS coils is similar in strength (often 1.5,T to 2,T) to that used in a standard MRI scanner. However, the area of the magnetic field generated by the TMS coil is much smaller and more focused.


Q: Does TMS require anesthesia or sedation?

No, TMS is a non-invasive procedure that is performed while the patient is awake and alert. It is designed to work without the use of general anesthesia or any form of sedation.


Q: Do the side effects of TMS worsen over the course of treatment?

Official medical information indicates that common side effects, such as mild scalp pain or headache, are generally transient. These effects are often observed to decrease and improve over time as the patient progresses through their treatment sessions.


Q: Is TMS an accepted standard of care in medical practice?

TMS is an FDA-cleared treatment that is considered medically necessary and indicated for adults with MDD who meet specific clinical criteria. Its use is guided by authoritative clinical determinations issued by health bodies.


Q: Can I listen to music or read during a TMS session?

Since patients are awake and alert, some patients are permitted to read or listen to music during the procedure. However, due to the loud clicking noise produced by the coil, the use of earplugs is part of the standard safety protocol.


Q: Is TMS effective for anxiety disorders?

Specific TMS devices have received FDA clearance for the treatment of Major Depressive Disorder (MDD) when comorbid (occurring alongside) anxiety symptoms are present. Official regulatory clearance is for the use in Major Depressive Disorder.


Q: What is the typical age range of people who receive TMS treatment?

FDA clearances for TMS devices indicate treatment availability for a broad range, including adults and adolescents aged 15 to 21 years who have Major Depressive Disorder.


Q: If TMS works for me, will I need 'maintenance' sessions later on?

The primary focus of clinical guidelines is the initial course of treatment. However, retreatment protocols are permitted for patients who experience a documented relapse of symptoms after achieving a positive response.


Q: Does TMS affect sleep patterns?

Sleep disruption is listed in clinical guidance documents as one of the common, mild side effects that may occur following a TMS session.


Q: What kind of specialist typically administers TMS?

TMS treatment must be ordered by a psychiatrist (MD or DO) familiar with the therapy. The treatment itself is administered under the direct supervision of a qualified professional in a clinical setting.


Q: Is it normal to feel a twitching sensation in the face during TMS?

Yes, common and mild side effects that may occur during the procedure include a tingling, spasm, or twitching sensation in the facial or scalp muscles.


Q: Is there a limit to the number of TMS courses a person can receive?

Official medical necessity criteria define an initial course of treatment. The criteria also allow for retreatment if a patient experiences a documented relapse of symptoms after a previous successful response.


Q: How is the targeted brain area located before a TMS session?

The precise targeted area is located using a process called 'mapping' that occurs before treatment begins. This mapping procedure is used to accurately determine the placement of the coil over the specific cortical region for the treatment.


Q: Do I need a referral from a physician to start TMS treatment?

TMS treatment must be ordered and overseen by a licensed physician, typically a psychiatrist, who has examined the individual and has the necessary experience with administering the therapy.

How should TMS be stored and disposed of?

How to Store and Dispose of Tiemonium Methylsulfate (TMS)

Official regulatory guidelines dictate specific storage and disposal requirements for Tiemonium Methylsulfate (TMS) to maintain its stability and ensure safety.


Storage Requirements

TMS must be stored at room temperature, not exceeding 30 C. The medicine requires protection from light and moisture and should be kept in its original container, which must be tightly closed. For safety, it is a mandatory requirement to store the product out of the sight and reach of children.


Disposal Instructions

Unused or expired Tiemonium Methylsulfate should not be disposed of in household trash or flushed down the toilet (wastewater). Disposal must instead follow local pharmaceutical waste regulations, often by returning the product to a pharmacy or authorized collection site for destruction.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of TMS found in:

A-Z Index: